XTalks

FEBRUARY 7, 2023

HR+/HER2- breast cancer is the most common type of breast cancer, with the National Cancer Institute (NCI) estimating 287,850 new cases of female breast cancer in 2022 alone. Despite decades of advances, people living with pre-treated HR+/HER2- metastatic breast cancer need new treatment options. months vs. 11.2

HR 52

HR Hormones FDA Approval Antibody 52

pharmaphorum

JUNE 17, 2022

Developed by Pfizer, Paxlovid was granted emergency use authorization (EUA) to treat COVID-19 patients based on the EPIC-HR study which showed it reduced the risk of hospitalization or death by almost 90 percent. Paxlovid consists of two different drugs, nirmatrelvir 150mg tablets co-packaged with ritonavir 100mg tablets.

Drugs 105

Drugs Clinical Trials Clinical Trials HR 105

The Pharma Data

AUGUST 30, 2021

KEYTRUDA in combination with chemotherapy (pac, nab-paclitaxel or gem/carbo) reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.49, 0.86]; p=0.0012), with a median PFS of 9.7 months (95% CI, 7.6-11.3) months (95% CI, 5.3-7.5), 7.5), versus the same chemotherapy regimens alone in these patients. months [95% CI, 5.4-32.4]

Hormones 52

Hormones HR Trials Protein 52

The Pharma Data

MARCH 20, 2021

Previous studies have suggested that detection of viral proteins in body fluids could be a rapid diagnostic method for severe acute respiratory syndrome (SARS) ( 19 – 21 ). Nucleocapsid protein from SARS patients was abundant enough to be detected in clinical samples using an ELISA approach ( 20 ). RESULTS AND DISCUSSION.

Protein 52

Protein Antibody Development RNA 52

Pfizer

AUGUST 15, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. 07.27.2022.

Drugs 99

Drugs Vaccine Vaccination In-Vitro 99

Pfizer

DECEMBER 13, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course.

Drugs 110

Drugs Licensing Licensing Production 110

XTalks

AUGUST 2, 2023

2) Paxlovid (nirmatrelvir/ritonavir) Paxlovid is a dual-packaged oral medication for the treatment of COVID-19. 5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. billion in 2022, a 6.45

Sales 98

Sales Manufacturing FDA Approval Life Science 98